Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial

References

• Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670:244–251. doi:10.1016/j.ejphar.2011.08.02221920359
   PubMed Web of Science ®Google Scholar
• Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013;52:37–42. doi:10.1007/s40262-012-0021-x23184737
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012;67:35–41. doi:10.1136/thoraxjnl-2011-20030821828231
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106:642–650. doi:10.1016/j.rmed.2012.01.00422342538
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014;108:41–49. doi:10.1016/j.rmed.2013.11.00924295556
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Resir Res. 2011;12:160. doi:10.1186/1465-9921-12-160
   PubMed Web of Science ®Google Scholar
• van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079. doi:10.1038/npjpcrm.2016.7927883002
   PubMed Web of Science ®Google Scholar
• Takaku Y, Kurashima K, Ohta C, et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med. 2017;123:110–115. doi:10.1016/j.rmed.2016.12.01228137486
   PubMed Web of Science ®Google Scholar
• Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5:1071–1081. doi:10.1016/j.jaip.2017.01.00428286157
   PubMed Web of Science ®Google Scholar
• Busse WW, O’Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial. Thorax. 2013;68:513–520. doi:10.1136/thoraxjnl-2012-20260623440247
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Lötvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144:1222–1229. doi:10.1378/chest.13-017823846316
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43:773–782. doi:10.1183/09031936.0006451324136330
   PubMed Web of Science ®Google Scholar
• Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69:312–319. doi:10.1136/thoraxjnl-2013-20360024253831
   PubMed Web of Science ®Google Scholar
• Dwan K, Milan SJ, Bax L, Walters N, Powell C. Vilanterol and fluticasone furoate for asthma. Cochrane Database Syst Rev. 2016;9:CD010758.27582089
   PubMed Web of Science ®Google Scholar
• Woodcock A, Vestbo J, Bakerly ND, et al. Salford Lung Study Investigators, effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390:2247–2255. doi:10.1016/S0140-6736(17)32397-828903864
   PubMed Web of Science ®Google Scholar
• Devillier P, Humbert M, Boye A, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: an open-label, randomized, controlled trial. Respir Med. 2018;141:111–120. doi:10.1016/j.rmed.2018.06.00930053956
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. [updated 2018]. Available from:  https://ginasthma.org. Accessed 329, 2018.
   Google Scholar
• Standardization of spirometry. American Thoracic Society, 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136. doi:10.1164/ajrccm.152.3.76637927663792
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553–558. doi:10.1016/j.rmed.2004.10.00815823451
   PubMed Web of Science ®Google Scholar
• Juniper E, Bousquet J, Abetz L, Bateman ED, Committee TGOAL. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the asthma control questionnaire. Respir Med. 2006;100:616–621. doi:10.1016/j.rmed.2005.08.01216226443
   PubMed Web of Science ®Google Scholar
• Shirai T, Furuhashi K, Suda T, Chida K. Relationship of the asthma control test with pulmonary function and exhaled nitric oxide. Ann Allergy Asthma Immunol. 2008;101:608–613. doi:10.1016/S1081-1206(10)60223-219119704
   PubMed Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117:549–556. doi:10.1016/j.jaci.2006.01.01116522452
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–930. doi:10.1164/rccm.200406-710ST15817806
   PubMed Web of Science ®Google Scholar
• Matza LS, Park J, Coyne KS, Skinner EP, Malley KG, Wolever RQ. Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother. 2009;43:1621–1630. doi:10.1345/aph.1M17419776298
   PubMed Web of Science ®Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24 hr duration of action. J Pharmacol Exp Ther. 2013;344:218–230. doi:10.1124/jpet.112.19848123131596
   PubMed Web of Science ®Google Scholar
• Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharmacists. Respir Med. 2011;105:1815–1822. doi:10.1016/j.rmed.2011.07.00421802271
   PubMed Web of Science ®Google Scholar
• Al-Jahdali H, Ahmed A, Al-Harbi A, et al. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin. Immunol. 2013;9:8. doi:10.1186/1710-1492-9-823510684
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi:10.1097/00005650-198601000-000073945130
   PubMed Web of Science ®Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–247. doi:10.1016/S0920-9964(99)00130-910785582
   PubMed Web of Science ®Google Scholar
• Matza LS, Yu-Isenberg KS, Coyne KS, et al. Further testing of the reliability and validity of the ASK-20 adherence barrier questionnaire in a medical center outpatient population. Curr Med Res Opin. 2008;24:3197–3206. doi:10.1185/0300799080246364218922213
   PubMed Web of Science ®Google Scholar
• Hahn SR, Park J, Skinner EP, et al. Development of the ASK-20 adherence barrier survey. Curr Med Res Opin. 2008;24:2127–2138. doi:10.1185/0300799080217476918554431
   PubMed Web of Science ®Google Scholar
• Atsuta R, To Y, Sakamoto S, et al. Assessing usability of the “Adherence Starts with Knowledge 20” (ASK-20) questionnaire for Japanese adults with bronchial asthma receiving inhaled corticosteroids long term. Allergol Int. 2017;66:411–417. doi:10.1016/j.alit.2016.09.00127712949
   PubMed Web of Science ®Google Scholar
• Toyama T, Kawayama T, Kinoshita T, et al. Differences in adherence barriers to inhaled medicines between Japanese patients with chronic obstructive pulmonary disease and asthma evaluated using the “Adherence Starts with Knowledge 20” (ASK-20) questionnaire. Intern Med. 2019;58:175–185. doi:10.2169/internalmedicine.0488-1730210101
   PubMed Web of Science ®Google Scholar
• Takemura M, Nishio M, Fukumitsu K, et al. Optimal cut-off value and clinical usefulness of the Adherence Starts with Knowledge-12 in patients with asthma taking inhaled corticosteroids. J Thorac Dis. 2017;9:2350–2359. doi:10.21037/jtd28932539
   PubMed Web of Science ®Google Scholar